Bristol Myers Squibb (NYSE:BMY) Announces Quarterly Earnings Results

Bristol Myers Squibb (NYSE:BMY) issued its quarterly earnings results on Thursday. The biopharmaceutical company reported $1.26 EPS for the quarter, missing analysts’ consensus estimates of $1.65 by ($0.39), FiscalAI reports. Bristol Myers Squibb had a return on equity of 76.53% and a net margin of 12.57%.The company had revenue of $12.50 billion during the quarter, compared to analysts’ expectations of $12.24 billion. During the same quarter in the previous year, the company earned $1.67 EPS. The business’s quarterly revenue was up 1.3% compared to the same quarter last year. Bristol Myers Squibb updated its FY 2026 guidance to 6.050-6.350 EPS.

Here are the key takeaways from Bristol Myers Squibb’s conference call:

• Growth portfolio momentum — Growth portfolio revenue rose ~15% in Q4 and 17% for FY2025, with Opdualag, Breyanzi and Camzyos each >$1B and Reblozyl >$2B, and those newer products nearly offset a ~ $4B decline in the legacy portfolio.
• Data-rich pipeline in 2026 — BMS expects top-line registrational readouts for six potential new products and >10 pivotal readouts this year (examples: Milvexian, Admilparant, Iberdomide, Mezigdomide, RYZ101, Sotyktu and Cobenfy extensions), concentrated in H2 and positioned as key near-term catalysts.
• 2026 financial guide — Company guided 2026 revenue of $46.0–$47.5B, gross margin ~69%–70%, operating expenses ~ $16.3B and adjusted EPS of $6.05–$6.35, while noting continued reinvestment into launches and selected development programs.
• Eliquis transition risk — Eliquis is expected to grow 10%–15% in 2026 (helped by pricing/contract changes), but management anticipates a $1.5–$2.0B step-down in 2027 driven by generic entry and EU patent expirations late‑2026.
• Cost, cash and capital allocation — BMS delivered ~ $1B of a $2B productivity target in 2025, expects the remaining $1B across 2026–27, holds ~ $11B cash/marketable securities, completed a targeted $10B debt paydown and plans continued BD plus dividend returns.

Bristol Myers Squibb Trading Up 3.8%

BMY traded up $2.21 on Thursday, hitting $59.83. The company had a trading volume of 15,793,412 shares, compared to its average volume of 13,048,385. The business’s fifty day simple moving average is $53.88 and its 200 day simple moving average is $48.85. The company has a quick ratio of 1.17, a current ratio of 1.27 and a debt-to-equity ratio of 2.39. Bristol Myers Squibb has a 12-month low of $42.52 and a 12-month high of $63.33. The company has a market cap of $121.80 billion, a PE ratio of 20.26, a PEG ratio of 0.17 and a beta of 0.29.

Bristol Myers Squibb Increases Dividend

The firm also recently declared a quarterly dividend, which was paid on Monday, February 2nd. Investors of record on Friday, January 2nd were issued a $0.63 dividend. This represents a $2.52 dividend on an annualized basis and a dividend yield of 4.2%. The ex-dividend date of this dividend was Friday, January 2nd. This is a positive change from Bristol Myers Squibb’s previous quarterly dividend of $0.62. Bristol Myers Squibb’s payout ratio is 85.14%.

Analysts Set New Price Targets

A number of equities analysts have weighed in on BMY shares. Cantor Fitzgerald reiterated a “neutral” rating on shares of Bristol Myers Squibb in a research report on Monday, November 24th. Leerink Partners upped their target price on shares of Bristol Myers Squibb from $54.00 to $60.00 and gave the stock an “outperform” rating in a report on Tuesday, January 13th. Bank of America raised Bristol Myers Squibb from a “neutral” rating to a “buy” rating and raised their price target for the company from $52.00 to $61.00 in a report on Monday, December 15th. Truist Financial set a $65.00 target price on Bristol Myers Squibb in a research report on Wednesday, December 3rd. Finally, Wall Street Zen raised Bristol Myers Squibb from a “buy” rating to a “strong-buy” rating in a report on Saturday, November 8th. Seven investment analysts have rated the stock with a Buy rating, twelve have assigned a Hold rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat, the company currently has a consensus rating of “Hold” and an average price target of $57.43.

Trending Headlines about Bristol Myers Squibb

Here are the key news stories impacting Bristol Myers Squibb this week:

• Positive Sentiment: Q4 revenue beat and growth portfolio strength — BMY reported Q4 revenue of $12.5B with its Growth Portfolio up ~16%, which investors cited as the main operational upside supporting the stock. Bristol-Myers Stock Up as Q4 Earnings and Revenues Beat Estimates
• Positive Sentiment: Upbeat 2026 guidance — BMY raised its fiscal‑2026 outlook (EPS range 6.05–6.35; revenue $46.0–$47.5B), above consensus, and said expected Eliquis pricing moves should help revenue next year — a key reason traders pushed the stock higher. Bristol Myers forecasts upbeat 2026
• Positive Sentiment: Expanded CAR‑T manufacturing partnership — BMY signed a multi‑year commercial supply agreement with OXB for lentiviral vectors, strengthening capacity for cell & gene therapy programs and adding a longer‑term growth catalyst. OXB Signs New Multi-Year Commercial Supply Agreement with Bristol Myers Squibb
• Neutral Sentiment: Macro noise — weekly U.S. jobless claims rose to the highest weekly print since early December, adding broader market volatility on an otherwise stock‑specific earnings day. That may have amplified share moves but is not directly company‑specific. Weekly Jobless Claims Exceed Expectations
• Neutral Sentiment: Pre‑earnings volatility and analyst notes — shares were already volatile into the print as investors digested analyst commentary and the expanded OXB deal. What’s Going On With Bristol-Myers Squibb Stock Today?
• Negative Sentiment: EPS dynamics mixed — headline non‑GAAP EPS prints were varied across outlets (reported $1.26), and EPS is down year‑over‑year from $1.67 a year ago; some consensus comparisons show a miss depending on the metric, which keeps scrutiny on margins and legacy product erosion. Earnings details and call links
• Negative Sentiment: Legacy‑drug headwinds — several older products continue to decline, tempering how quickly top‑line growth can accelerate despite immuno‑oncology gains. Revenue ticks up on immuno-oncology growth

Institutional Trading of Bristol Myers Squibb

Hedge funds and other institutional investors have recently bought and sold shares of the stock. Brighton Jones LLC raised its position in Bristol Myers Squibb by 33.4% in the 4th quarter. Brighton Jones LLC now owns 19,728 shares of the biopharmaceutical company’s stock worth $1,116,000 after purchasing an additional 4,935 shares during the period. Sivia Capital Partners LLC grew its stake in shares of Bristol Myers Squibb by 59.4% during the second quarter. Sivia Capital Partners LLC now owns 7,477 shares of the biopharmaceutical company’s stock valued at $346,000 after buying an additional 2,786 shares during the last quarter. United Bank raised its holdings in shares of Bristol Myers Squibb by 15.0% in the second quarter. United Bank now owns 25,148 shares of the biopharmaceutical company’s stock worth $1,164,000 after buying an additional 3,277 shares during the period. Marshall Wace LLP purchased a new position in Bristol Myers Squibb during the 2nd quarter valued at $221,000. Finally, Nebula Research & Development LLC purchased a new stake in shares of Bristol Myers Squibb during the second quarter valued at $405,000. Hedge funds and other institutional investors own 76.41% of the company’s stock.

About Bristol Myers Squibb

Bristol Myers Squibb is a global biopharmaceutical company headquartered in Princeton, New Jersey, focused on discovering, developing and delivering medicines for serious diseases. The company’s core activities include research and development, clinical development, manufacturing and commercialization of prescription pharmaceuticals across multiple therapeutic areas. BMS concentrates on advancing therapies in oncology, hematology, immunology, cardiovascular disease and specialty areas through both small molecules and biologics.

BMS’s marketed portfolio and late‑stage pipeline reflect a strong emphasis on cancer and immune‑mediated conditions.